|
Name |
7-hydroxy-13-dehydroxypaxilline
|
| Molecular Formula | C27H33NO4 | |
| IUPAC Name* |
5-hydroxy-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-8-one
|
|
| SMILES |
CC(C)(O)C1OC2(O)CCC3(C)C(CCC4Cc5c([nH]c6ccccc56)C43C)C2=CC1=O
|
|
| InChI |
InChI=1S/C27H33NO4/c1-24(2,30)23-21(29)14-19-18-10-9-15-13-17-16-7-5-6-8-20(16)28-22(17)26(15,4)25(18,3)11-12-27(19,31)32-23/h5-8,14-15,18,23,28,30-31H,9-13H2,1-4H3/t15-,18-,23-,25-,26+,27-/m0/s1
|
|
| InChIKey |
JFVYPWSFDLYZKB-XTHGXZEWSA-N
|
|
| Synonyms |
NA
|
|
| CAS | NA | |
| PubChem CID | NA | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 435.56 | ALogp: | 4.2 |
| HBD: | 3 | HBA: | 4 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 82.5 | Aromatic Rings: | 6 |
| Heavy Atoms: | 32 | QED Weighted: | 0.604 |
| Caco-2 Permeability: | -4.829 | MDCK Permeability: | 0.00001740 |
| Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.005 |
| Human Intestinal Absorption (HIA): | 0.024 | 20% Bioavailability (F20%): | 0.012 |
| 30% Bioavailability (F30%): | 0.015 |
| Blood-Brain-Barrier Penetration (BBB): | 0.805 | Plasma Protein Binding (PPB): | 94.60% |
| Volume Distribution (VD): | 2.476 | Fu: | 3.02% |
| CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.938 |
| CYP2C19-inhibitor: | 0.234 | CYP2C19-substrate: | 0.921 |
| CYP2C9-inhibitor: | 0.364 | CYP2C9-substrate: | 0.498 |
| CYP2D6-inhibitor: | 0.038 | CYP2D6-substrate: | 0.396 |
| CYP3A4-inhibitor: | 0.761 | CYP3A4-substrate: | 0.928 |
| Clearance (CL): | 8.776 | Half-life (T1/2): | 0.128 |
| hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.219 |
| Drug-inuced Liver Injury (DILI): | 0.454 | AMES Toxicity: | 0.893 |
| Rat Oral Acute Toxicity: | 0.932 | Maximum Recommended Daily Dose: | 0.443 |
| Skin Sensitization: | 0.111 | Carcinogencity: | 0.481 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.02 |
| Respiratory Toxicity: | 0.981 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC005988 | ![]() |
0.828 | D0H4JM | ![]() |
0.281 | ||
| ENC002279 | ![]() |
0.725 | D0U7GP | ![]() |
0.281 | ||
| ENC000836 | ![]() |
0.712 | D01JGV | ![]() |
0.281 | ||
| ENC005989 | ![]() |
0.615 | D05MQK | ![]() |
0.263 | ||
| ENC003172 | ![]() |
0.615 | D0V4WD | ![]() |
0.262 | ||
| ENC003876 | ![]() |
0.613 | D04GJN | ![]() |
0.256 | ||
| ENC002951 | ![]() |
0.611 | D0Q6NZ | ![]() |
0.250 | ||
| ENC001492 | ![]() |
0.603 | D0K0KH | ![]() |
0.250 | ||
| ENC005406 | ![]() |
0.600 | D0U3GL | ![]() |
0.250 | ||
| ENC005405 | ![]() |
0.573 | D06AEO | ![]() |
0.250 | ||